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Summary We assessed the therapeutic significance of systematic aortic and pelvic lymphadenectomy followed by adjuvanttherapy in node-
positive endometrial carcinoma. Among 173 stage lll patients, 30 (17%) had positive nodes: ten in the pelvic region alone (group P) and 20
in the aortic region alone or in both regions (group A). The adjuvant therapy was administered as follows: subjects in group P received 50 Gy
pelvic radiation, including three post-surgical T3 (pT3) patients who received either one or three cycles of cisplatin-based chemotherapy
before radiation. Subjects in group A were given three cycles of chemotherapy followed by 50 Gy pelvic and 50 Gy extended field periaortic
radiation using a four-field or conformational technique. Five-year survival was 95% for 143 patients with negative nodes and 84% for 30
patients with positive nodes (100% for group P and 75% for groupA). In group A, 5-year survival was 38% for eight patients with both pT3 and
histology other than endometrioid type Gl, and 91% forthe remaining 12 patients. Eitherway, both group P and group A patients had a better
prognosis than previously reported. In summary, aortic and pelvic lymphadenectomy and subsequent chemotherapy and radiation therapy
based on node status seem to improve the survival of endometrial cancer patients with positive nodes.
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Based on the FIGO (the International Federation of Gynecology
and Obstetrics) staging system proposed in 1988, patients with
positive aortic or pelvic nodes are classified as having stage IIIC
disease (Creasman, 1990), which is associated with the poorest
prognosis among patients without distant metastases. The survival
of stage IIIC patients ranges from 0% to 56% throughout the liter-
ature (Potish et al, 1985; Larson et al, 1987; Greven et al, 1993).
Various procedures have been used to assess aortic and pelvic
nodes in endometrial cancer, i.e. biopsies from enlarged nodes
only, selective nodal sampling from multiple sites, pelvic
lymphadenectomy and aortic and pelvic lymphadenectomy. It is
obvious that aortic and pelvic lymphadenectomy is most accurate
ofthese methods. However, aortic and pelvic lymphadenectomy is
not regarded as the standard surgical procedure for endometrial
cancer, even among patients at high risk for lymph node metas-
tases, because the therapeutic significance ofthe procedure has not
yet been sufficiently demonstrated (Calais et al, 1990; Belinson et
al, 1992; Kim et al, 1993; Faught et al, 1994; Chuang et al, 1995;
Kilgore et al, 1995).
Feuer et al (1987) and Rose et al (1992) reported that post-
surgical radiotherapy was effective for microscopic node meta-
stases of endometrial cancer, whereas it had no favourable effect
on macroscopic node metastases. On the other hand, the response
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rate of chemotherapy for endometrial cancer has been reported to
be 30-57% (Seski et al, 1982; Hancock et al, 1986; Green et al,
1990), which is still lower than that for ovarian cancer. Hence, the
rational treatment of endometrial cancer with positive lymph
nodes is not clarified.
In an attempt to improve treatment results ofendometrial cancer
patients with positive lymph nodes, we examined the therapeutic
value of systematic aortic and pelvic lymphadenectomy followed
by radiation therapy or chemotherapy plus radiation therapy,
depending on node status. We also investigated the incidence and
distribution of node metastases in relation to various prognostic
variables ofendometrial cancer.
PATIENTS AND METHODS
Patient selection
From July 1986 to March 1996, we performed systematic aortic
and pelvic lymphadenectomy in addition to hysterectomy and
bilateral salpingo-oophorectomy in 173 stage I-111 endometrial
cancer patients treated at the Department of Obstetrics and
Gynecology, University of Tokyo Hospital, or at the Department
of Obstetrics and Gynecology, the Tokyo Metropolitan
Komagome Hospital. The mean age of the 173 patients was 55.8
years (range 30-77 years), with the median follow-up being 50
months (range 4-111 months), exclusive ofdeath cases.
Histological type and grade, myometrial invasion and post-
surgical T (pT) classification ofthe 173 patients are shown in Table
1. Definition of stage and TNM classification are as follows: stage
I (pTlNOMO); tumour confined to the corpus (TI), no evidence of
lymph node metastasis (NO), no evidence of distant metastasis
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Table 1 Histological type and grade, myometrial invasion and pT
classification of the stage I-Ill patients who underwent aortic and pelvic
lymphadenectomy
Histological type and grade No. of patients pT classification
pT1 pT2 pT3
Endometrioid
Gl 97 63 15 19
G2 55 33 6 16
G3 10 6 1 3
Adenosquamous 9 3 4 2
Clear cell 1 0 0 1
Squamous 1 1 0 0
Total 173 106 26 41
Myometrial invasion
< 1/3 93 66 11 16
1/3-2/3 35 21 7 7
> 2/3 45 19 8 18
Total 173 106 26 41
Table 2 Incidence of lymph node metastases in relation to various prognostic
factors
No. of patients Lymph node metastases
Pelvic (%) Aortic (%) Total (%)
pT classification
pTl
pT2
pT3a
Histological type and grade
Endometrioid
Gl
G2
G3
Adenosquamous
Clear cell
Squamous
Myometrial invasion
< 1/3
1/3-2/3
> 2/3
Overall
106
26
41
97
55
10
9
1
1
93
35
45
10 (9%)
4 (15%)
14 (34%)
8 (8%)
15 (27%)
1 (10%)
3 (33%)
1 (100%)
0 (0%)
8 (9%)
6 (17%)
14 (31%)
4 (4%)
4 (15%)
12 (29%)
5 (5%)
12 (22%)
0 (0%)
2 (22%)
1 (100%)
0 (0%)
4 (4%)
4 (11%)
12 (27%)
10 (9%)
5 (19%)
15 (37%)
9 (9%)
16 (29%)
1 (10%)
3 (33%)
1 (100%)
0 (0%)
8 (9%)
6 (17%)
16 (36%)
173 28 (16%) 20 (12%) 30 (17%)
(MO); stage II (pT2NOMO), tumour invades the cervix but does not
extend beyond the uterus (T2); stage IIIA (pT3ANOMO), tumour
invades serosa and/or adnexa (direct extension or metastasis)
and/or cancer cells in ascites or peritoneal washings (T3A); stage
IIIB (pT3BNOMO), vaginal involvement (direct extension or
metastasis) (T3B); stage IIIC (pTI-3NIMO), evidence of lymph
node metastasis (NI).
Surgery
Operative procedure included hysterectomy, bilateral salpingo-
oophorectomy and systematic aortic andpelvic lymphadenectomy.
Radical hysterectomy was performed on 66 patients with
positive findings on presurgical endocervical curettage and total
hysterectomy on the remainder, who were negative for endo-
cervical curettage.
The procedure of systematic lymphadenectomy performed in
this study represents complete dissection oflymph nodes from the
femoral ring caudally up to the upper margin ofthe renal vessels.
To achieve this, we mobilized the ascending colon, the descending
colon and the duodenum, and displaced them to the right, to the
left and upwards respectively, so that para-aortic retroperitoneal
space was widely developed up to the renal vessels. All lymphatic
tissues surrounding the retroperitoneal vessels were completely
removed. The average number (range) ofnodes removed was 66.7
(37-96): 28.7 for the aortic nodes (10-49) and 37.9 for the pelvic
nodes (23-57).
All 173 patients had no residual tumours after completion of
surgery including the ablation ofperitoneal implants.
Chemotherapy
Post-surgically, the patients with either adnexal/peritoneal involve-
ment or aortic node metastases were treated with three cycles of
chemotherapy (CAPregimen) at 3 weeks' interval followedby radi-
ation therapy. The patients who did not meet the above criteria and
hadpositiveperitoneal cytology weretreated with onecycleofCAP.
The CAP regimen consisted of cyclophosphamide 600mg m72,
doxorubicin 40 mg m-2 and cisplatin 75 mg m-2. Each anti-cancer
drug was administered intravenously on the same day.
aAll 41 patients were categorized as pT3A.
Radiation therapy
Whole-pelvis irradiation was indicated when at least one of the
following factors existed: positive pelvic lymph nodes, deep
myometrial invasion (more than two-thirds invasion in endo-
metrioid Gl, more than one-third in other types or grades), pelvic
peritoneal metastases and adnexal metastases. The periaortic irra-
diation was administered to aortic node-positive patients.
Bothpelvic andperiaortic radiation treatments consisted of50Gy
administered in 2-Gy fractions, five times per week for 5 weeks.
The periaortic irradiation was administered with 10 MeV X-rays
employing a conformational technique using computer planning or
with a four-field [anterior-posterior (7 cm wide) and lateral (6 cm
wide) fields] technique (Corn et al, 1992) from the upper margin of
the fifth lumbar vertebral body to that ofthe 11th thoracic vertebral
body. Both methods wereplanned todeliver50-Gydosages to aortic
node region and 25 Gy or less in large part ofperitoneal cavity and
the bone marrow of lumbar and thoracic vertebral bodies.
Radiotherapy was initiated 3 weeks afterchemotherapy.
Statistical methods
Survival curves were determined by the Kaplan-Meier product
limit method (Kaplan et al, 1958). Analysis of the differences
between survival curves was performed using the log-rank test. A
multifactorial approach (Cox proportional-hazards regression
analysis) was performed in analysing the prognostic factors using
a JMP program.
RESULTS
Incidence and distribution of lymph node metastases
The overall incidence of retroperitoneal lymph node metastases
assessed by systematic aortic and pelvic lymphadenectomy was
17% (30/173) in stage I-III endometrial cancer. The incidences of
aortic and pelvic lymph node metastases were 12% (20/173) and
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16% (28/173) respectively (Table 2). More precisely, two patients
had lymph node metastases in the aortic region alone, ten in the
pelvic region alone and 18 in both regions.
We examined the incidences of aortic and pelvic node metas-
tases in relation to pT classification, histological type and grade
and depth of myometrial invasion (Table 2). The incidences of
positive lymph nodes were 9% in pTl, 19% in pT2 and 37% in
pT3. The incidences of positive aortic and pelvic nodes were,
respectively, 4% and 9% in pTl, 15% and 15% in pT2 and 29%
and 34% in pT3. As for histological type, the incidences of node
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33% (3/9) in adenosquamous carcinoma, 100% (1/1) in clear cell
adenocarcinoma and 0% (0/1) in squamous cell carcinoma. In rela-
tion to grade of endometrioid adenocarcinoma, the incidences of
node metastases were 9% (9/97) in GI, 29% (16/55) in G2 and
10% (1/10) in G3 tumours. The incidence of node metastases
increased with depth of maximal myometrial invasion such that
node metastases were found in 9% (8/93) of patients with the
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Figure 1 Survival ofpatients with stage I/Il, IIA and 1110 endometrial cancer who underwent systematic lymphadenectomy
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Figure 2 Survival of stage 1110 endometrial cancer patients according to localization of the node metastases
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Figure 3 Survival of aortic node-positive endometrial cancer patients with or without risk factors of both histology other than endometrioid Gl and pT3
myometrial invasion (middle one-third) and 36% (16/45) of
patients with deep myometrial invasion (outer one-third).
Adjuvant therapy of the node-positive patients
All 30 endometrial cancer patients with lymph node metastases
were treated according to the treatment programme as described in
'Patients and methods'. As a result, 20 patients with aortic node
metastases (group A) had both whole pelvis irradiation and
periaortic irradiation after three cycles of CAP, because pelvic irra-
diation was administered in 18 patients for concomitant pelvic
node metastases and in two patients for deep myometrial invasion.
Of the remaining ten patients with pelvic node metastases alone
(group P), one patient had one cycle of CAP for positive peritoneal
cytology and two had three cycles of CAP for adnexal metastases
followed by whole-pelvis irradiation.
Looking at the accomplishment of the treatment, no patients
required major modification of treatment modality because of
acute complications such as myelosuppression and enteritis. One
patient developed partial small bowel obstruction that required the
surgery of affected bowel and reanastomosis 36 months after
pelvic and periaortic irradiation.
Survival
Five-year survival was 93% for all the 173 stage I-I11 patients.
Figure shows the survival data in relation to FIGO stage. Five-
year survival of the patients with stage M/I, IIIA, IIIC was 95%,
96% and 84% respectively.
Survival of the patients with lymph node metastases (the stage
IIIC patients) was analysed according to localization of the node
metastases (Figure 2). Five-year survival was 75% for the patients
with aortic node metastases irrespective of pelvic node metastases
(group A) and 100% for those with pelvic node metastases alone
(group P).
We further analysed correlation between the survival of group A
patients and various prognostic factors such as pT classification,
histology and grade and depth of myometrial invasion. Five-year
survival was 88% for patients with pTI/2 disease and 62% for
those with pT3 disease (P = 0.30, not significant), 100% for the
patients with endometrioid Gl cancer and 68% for those with
histology other than endometrioid GI (P = 0.26, not significant),
75% for the patients with superficial myometrial invasion (less
than one-third) and 75% for those with moderate to deep myo-
metrial invasion (beyond one-third) (P = 0.76, not significant).
Multifactorial analysis revealed no significant correlation between
survival in group A and each prognostic factor.
These results suggested that histology other than endometrioid
GI and pT3 seemed to be associated with poor prognosis in group
A, although the differences were not statistically significant.
Subsequently, we compared the survival curve for patients with
these two prognostic factors (histology other than endometrioid
GlI and pT3) with that for patients with one or none of these
factors (Figure 3). Five-year survival among patients with both
prognostic factors was significantly poorer than for those with one
or no prognostic factor (38% vs 91%, P < 0.05).
DISCUSSION
In this study, we analysed the prevalence and distribution of
metastatic aortic and pelvic lymph nodes and the survival of
endometrial cancer patients who underwent systematic aortic and
pelvic lymphadenectomy followed by irradiation or chemotherapy
plus irradiation, depending on node status.
The incidences of aortic and pelvic node' metastases in stage
endometrial cancer were 12% (20/173) and 16% (28/173)
respectively. Creasman et al (1987) (Gynecologic Oncology
Group) reported the incidences of aortic and pelvic node metas-
tases were 6% and 9% respectively. The incidences in the present
study were higher than those in previous reports (aortic nodes,
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1-9%; pelvic nodes, 9-15%) (Burrell et al, 1982; Boronow et al,
1984; Ayhan et al, 1989). The reason forthis may lie in differences
in the subjects examined, such that previous studies dealt with
patients with clinical (preoperative) stage I disease, whereas our
study included patients with stage I-III cancer. In addition, we
conducted lymph node dissection thoroughly, as reflected by an
average number of removed nodes of 66.7. This may, in part,
explain the high positive rates in our study.
Concerning the distribution of lymph node metastases, 93%
(28/30) of patients with node metastases had pelvic node metas-
tases and 64% (18/28) ofpatients with pelvic node metastases had
concomitant aortic node metastases. The high incidence of pelvic
node metastases accompanied by aortic node metastases is consis-
tent with previous reports (Boronow et al, 1984). In contrast, 33%
(10/30) of patients with node metastases had pelvic node metas-
tases alone and 7% (2/30) had aortic node metastases alone.
Creasman et al (1987) (GOG) also reported a higher incidence of
isolated pelvic node metastases (51% [36/70]) than of isolated
aortic node metastases (17% [12/70]) in clinical stage I endome-
trial cancer patients. These data suggest that in endometrial cancer
direct lymphatic spread to pelvic nodes occurs more frequently
than spread to the aortic nodes.
We correlated lymph node metastases with other prognostic
factors such as pT, histological type and grade, and myometrial
invasion. The incidence of lymph node metastases increased with
advancement of pT and depth of myometrial invasion. The inci-
dence of lymph node metastases was lower in endometrioid G1
than in endometrioid G2/G3 or other histological types. These
findings are consistent with previous reports on clinical stage I/lI
endometrial cancer (Burrell et al, 1982; Boronow et al, 1984;
Creasman et al, 1987; Ayhan et al, 1989; Calais et al, 1990;
Morrow et al, 1991).
pT3A is defined as the presence of adnexal metastases, pelvic
peritoneal implants and positive peritoneal cytology. Thus far,
these clinical manifestations that are characteristic of pT3A are
thought to be poor prognostic factors (Creasman et al, 1981;
Morrow et al, 1991; Greven et al, 1993; Kadar et al, 1994). The
present study demonstrated that 37% of pT3A patients had lymph
node metastases. Notably, when focusing on stage IIIA patients in
the pT3A group, we found a higher 5-year survival rate among the
patients with stage IIIA disease (96%) than among those with
stage 1/11 disease (95%). The good prognosis of the stage IIIA
(pT3ANO) patients in our study can be explained as follows.
Firstly, lymph node-positive patients (pT3AN1) could be
completely excluded by systematic lymphadenectomy. Secondly,
post-surgical chemotherapy with or without radiation therapy
performed in this study may in part account for the favourable
result. At any rate, this result is taken to imply that the setting
associated with pT3A does not necessarily represent an
unfavourable outcome.
Survival ofpatients with stage IIIC disease (84%) is much better
than that reported previously (Potish et al, 1985; Larson et al,
1987; Greven et al, 1993). We analysed the survival ofthe patients
with stage IIIC disease in relation to localization of node metas-
tases and found that positive aortic nodes were associated with
poorer prognosis than were positive pelvic nodes (75% vs. 100%).
Although metastasis to pelvic nodes has been reported to be as
poor a prognostic factor as metastasis to aortic nodes (41-67% 5-
year survival) (Potish et al, 1985; Calais et al, 1990), the present
study suggests that involvement ofpelvic lymph nodes alone does
not necessarily carry a poor prognosis. Kadar et al (1994) reported
that the 5-year survival was 82% for patients with pelvic node
metastases alone as assessed by pelvic and aortic lymphadenec-
tomy below the inferior mesenteric artery. In the present study,
over 60% of patients with positive pelvic nodes had concomitant
aortic node metastases, which could be an explanation for the
notion that metastasis to pelvic nodes is a poor prognostic factor.
The good prognosis of the patients with pelvic node metastases
alone (group P) may be attributed not only to our treatment
programme, but also to complete exclusion of the presence of
aortic node metastases by aortic lymphadenectomy.
In the present study, 5-year survival ofpatients with aortic node
metastases (group A) (75%) was much better than previously
reported (0-60%) (Komaki et al, 1983; Potish et al, 1985; Blythe
et al, 1986; Feuer et al, 1987; Larson et al, 1987; Coin et al, 1992;
Rose et al, 1992; Hicks et al, 1993; Kadar et al, 1994). In partic-
ular, aortic node-positive patients with pTl/2 or endometrioid GI
cancer had a good prognosis (91% 5-year survival). Corn et al
(1992) reported that significantly fewer recurrences occurred
among aortic node-positive patients who underwent nodal
debulking followed by extended field irradiation and thus
suggested that new systemic treatments are needed to resolve the
problem of distant failure of these patients. Our data suggest that
aortic and pelvic lymphadenectomy followed by adjuvant
chemotherapy and radiation therapy may improve the survival of
the endometrial cancer patients with positive aortic nodes.
As for the patients with aortic node metastases (group A), both
histology other than endometrioid GI and pT3 were shown to be
associated with poorer prognosis (38% 5-year survival). Hence,
aortic node metastasis still carries a poor prognosis, especially
when other prognostic factors such as histology other than
endometrioid G1 and pT3 are also present.
We conclude that aortic and pelvic lymphadenectomy followed
by chemotherapy and radiotherapy based on histological findings
of node status increases survival of endometrial cancer patients
with positive nodes. However, further challenging treatment
programmes may be necessary for aortic node-positive patients,
especially for those with poor prognostic factors such as histology
other than endometrioid GI and pT3.
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